Citadel Advisors’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Citadel Advisors’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-129,700	Closed	-$94K	–	10221
2019 Q3	$94K	Buy	129,700 +75,800	+141%	+$54.9K	﹤0.01%	8514
2019 Q2	$42K	Buy	53,900 +100	+0.2%	+$111	﹤0.01%	8784
2019 Q1	$66K	Buy	53,800 +17,400	+48%	+$19.8K	﹤0.01%	8722
2018 Q4	$31K	Buy	+36,400	New	+$41.1K	﹤0.01%	8614

Other funds holding NVLN

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Citadel Advisors's NVLN Position: Q4 2019 in Review

Citadel Advisors sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 119,560 shares — an estimated $87K sold.

Citadel Advisors first reported a position in NVLN in Q4 2017 and held it in 4 quarters. The position peaked at $87K in Q3 2019. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

Citadel Advisors reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
Citadel Advisors sold 119,560 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $87K.
Citadel Advisors first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2017 and held it in 4 quarters.
Citadel Advisors's Novelion Therapeutics Inc. Common Shares position peaked at $87K in Q3 2019.
7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.